Health Canada
Exzell Pharma Inc.
2026-10-07
The handling of standard operating procedures for good manufacturing practices was inadequate.
View the regulator's official sourceBy Country
Canada manufacturing-site findings
at manufacturing sites in this country 8,784 findings drawn from 1,711 published documents. The most recent cases are below; the full set is in search.
See all Canada findingsWhich agency cited it
Health Canada
8,735
US FDA
47
EMA (Europe)
2
Companies with the most findings
Recent findings
Health Canada
2628709 Alberta Ltd.
2026-09-25
No deficiencies were recorded.
View the regulator's official source
Health Canada
Georgian Reef Pharma
2026-09-24
The written procedures for recalls were inadequate.
See every finding in this document View the regulator's official source
Health Canada
Georgian Reef Pharma
2026-09-24
The assessment, documentation, and/or procedures for considering the resale of returned drugs were inadequate.
See every finding in this document View the regulator's official source
Health Canada
Georgian Reef Pharma
2026-09-24
The change control system was inadequate for ensuring changes are properly documented, evaluated, and/or approved.
See every finding in this document View the regulator's official source
Health Canada
Georgian Reef Pharma
2026-09-24
The handling of standard operating procedures for good manufacturing practices was inadequate.
See every finding in this document View the regulator's official sourceOther countries
These findings are a record of the moment each document was published. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out — do not read them as the current state; check the regulator's official announcements for the latest status. Counts are measured from public data as of 2026-10-20, and findings are extracted automatically from the regulator's published documents. “View official source” on each case links directly to that document.
